Table 1.
Patient characteristics
| Sex (female/male) | 1,154/1,940 (37.3/62.7) |
| Age (years) | 61.5 ± 8.4 |
| Duration of diabetes (years) | 8.0 ± 7.5 |
| Smoking status (Brinkman's Index <200/≥200) | 1,572/1,522 (50.8/49.2) |
| BMI (kg/m2) | 24.1 ± 3.5 |
| A1C (%) | 7.1 ± 1.2 |
| Presence of hypertension (%) | 2,352 (76.0) |
| SBP (mmHg) | 133 ± 18 |
| DBP (mmHg) | 80 ± 12 |
| Presence of dyslipidemia (%) | 2,356 (76.1) |
| Total cholesterol (mmol/l) | 4.88 ± 0.78 |
| HDL cholesterol (mmol/l) | 1.48 ± 0.42 |
| Triglycerides (mmol/l) | 1.41 ± 0.98 |
| Treatment approach for diabetes | |
| Diet alone | 541 (17.5) |
| Using oral hypoglycemic agent | 1,793 (58.0) |
| Sulfonylureas | 1,097 (35.5) |
| Thiazolidinediones | 368 (11.9) |
| Biguanides | 1,069 (34.6) |
| Using insulin | 760 (24.6) |
| Treatment approach for dyslipidemia | |
| Using statins | 894 (28.9) |
| Using other drugs | 162 (5.2) |
| MMP9 C-1562T polymorphism | |
| CC genotype (%) | 2,145 (69.3) |
| CT genotype (%) | 867 (28.0) |
| TT genotype (%) | 82 (2.7) |
| F12 C46T polymorphism | |
| CC genotype (%) | 386 (12.5) |
| CT genotype (%) | 1,412 (45.6) |
| TT genotype (%) | 1,296 (41.9) |
| vWF G1051A polymorphism | |
| GG genotype (%) | 985 (31.8) |
| GA genotype (%) | 1,534 (49.6) |
| AA genotype (%) | 575 (18.6) |
| PAI-1 4G/5G polymorphism | |
| 4G4G genotype (%) | 1,245 (40.2) |
| 4G5G genotype (%) | 1,423 (46.0) |
| 5G5G genotype (%) | 425 (13.7) |
| Cerebral infarction (%) | 322 (10.4) |
Data are n (%) or means ± SD.